Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), B. Gahn(Houston Methodist), Dirk Arnold(Asklepios Klinik Altona), Luisa Mantovani‐Löffler, S Daum(Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie), Peter Reichardt(Helios Hospital Berlin-Buch), Ralf‐Dieter Hofheinz(University of Mannheim), A. Florschütz(Städtisches Klinikum Dessau), Michael Kneba(Universitäts Hautklinik Kiel), Kirstin Breithaupt(Charité - Universitätsmedizin Berlin), Guido Schumacher(Charité - Universitätsmedizin Berlin), Peter Schlattmann(Kliniken Maria Hilf), Matthias Glanemann(Saarland University), Albrecht Kretzschmar(Roche (Switzerland)), Dmitry Bichev(Charité - Universitätsmedizin Berlin)
Annals of Oncology
June 27, 2012
10.1093/annonc/mds129
Cited by 70

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k